



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07K 14/435 ^(2006.01)

(86) International application number:
PCT/EP2011/064086

(48) Corrigendum issued on:
27.09.2017 Bulletin 2017/39

(87) International publication number:
WO 2012/022742 (23.02.2012 Gazette 2012/08)

(45) Date of publication and mention
of the grant of the patent:
09.08.2017 Bulletin 2017/32

(21) Application number: **11744024.8**

(22) Date of filing: **16.08.2011**

(54) **BINDING PROTEINS FOR HEPCIDIN**
BINDUNGSPROTEINE FÜR HEPCIDIN
PROTÉINES SE LIANT À L'HEPCIDINE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **16.08.2010 US 374199 P**

(43) Date of publication of application:
26.06.2013 Bulletin 2013/26

(60) Divisional application:
17185231.2

(73) Proprietor: **Pieris Pharmaceuticals GmbH**
85354 Freising-Weihenstephan (DE)

(72) Inventors:
• **TRENTMANN, Stefan**
85391 Allershausen (DE)
• **MATSCHINER, Gabriele**
80333 Muenchen (DE)
• **SKERRA, Arne**
85354 Freising (DE)
• **HUELSMEYER, Martin**
85395 Wolfersdorf (DE)
• **GILLE, Hendrik**
80634 München (DE)

• **JENSEN, Kristian**
84028 Landshut (DE)
• **BEL AIBA, Rachida Siham**
80469 München (DE)
• **CHRISTIAN, Hans-Juergen**
85368 Moosburg (DE)
• **HOHLBAUM, Andreas**
85307 Paunzhausen (DE)

(74) Representative: **Schiweck, Weinzierl & Koch**
Patentanwälte Partnerschaft mbB
Landsberger Straße 98
80339 München (DE)

(56) References cited:
WO-A1-2009/058797 WO-A2-03/029463
WO-A2-2006/056464

• **Anonymous: "Pieris Announces Preclinical In
Vitro and In Vivo Data for its Anticalin® PRS-080
Hepcidin Antagonist Drug Program", Pieris AG:
News and Events , 23 May 2011 (2011-05-23),
XP002661794, Retrieved from the Internet:
URL:<http://www.pieris-ag.com/news-events/2001-05-23-Pieris-Announces-Preclinical-In-Vitro-and-In-Vivo-Data.php> [retrieved on
2011-10-20]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- GEBAUER M ET AL: "Engineered protein scaffolds as next-generation antibody therapeutics", CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 13, no. 3, 1 June 2009 (2009-06-01), pages 245-255, XP026285197, CURRENT BIOLOGY LTD, LONDON, GB ISSN: 1367-5931, DOI: 10.1016/J.CBPA.2009.04.627 [retrieved on 2009-06-06]
- D. SCHONFELD ET AL: "An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 106, no. 20, 19 May 2009 (2009-05-19) , pages 8198-8203, XP055010048, ISSN: 0027-8424, DOI: 10.1073/pnas.0813399106
- JOLANTA MALYSZKO ET AL: "Neutrophil Gelatinase-Associated Lipocalin and Heparin: What Do They Have in Common and Is There a Potential Interaction?", KIDNEY AND BLOOD PRESSURE RESEARCH, vol. 33, no. 2, 1 January 2010 (2010-01-01), pages 157-165, XP055010065, ISSN: 1420-4096, DOI: 10.1159/000315436
- SKERRA A: "'ANTICALINS': A NEW CLASS OF ENGINEERED LIGAND-BINDING PROTEINS WITH ANTIBODY-LIKE PROPERTIES", REVIEWS IN MOLECULAR BIOTECHNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 74, no. 4, 1 June 2001 (2001-06-01), pages 257-275, XP001079016, ISSN: 1389-0352, DOI: 10.1016/S1389-0352(01)00020-4 cited in the application